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Abstract
Context—Knowledge of family cancer history is important for assessing cancer risk and guiding
screening recommendations.
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Objective—To quantify how often throughout adulthood clinically significant changes occur in
cancer family history that would result in recommendations for earlier or intense screening.
Design and Setting—Descriptive study examining baseline and follow-up family history data
from participants in the Cancer Genetics Network (CGN), a US national population-based cancer
registry, between 1999 and 2009.
Participants—Adults with a personal history, family history, or both of cancer enrolled in the
CGN through population-based cancer registries. Retrospective colorectal, breast, and prostate
cancer screening-specific analyses included 9861, 2547, and 1817 participants, respectively;
prospective analyses included 1533, 617, and 163 participants, respectively. Median follow-up
was 8 years (range, 0–11 years). Screening-specific analyses excluded participants with the cancer
of interest.
Main Outcome Measures—Percentage of individuals with clinically significant family
histories and rate of change over 2 periods: (1) retrospectively, from birth until CGN enrollment
and (2) prospectively, from enrollment to last follow-up.
Results—Retrospective analysis revealed that the percentages of participants who met criteria
for high-risk screening based on family history at ages 30 and 50 years, respectively, were as
follows: for colorectal cancer, 2.1% (95% confidence interval [CI], 1.8%–2.4%) and 7.1% (95%
CI, 6.5%–7.6%); for breast cancer, 7.2% (95% CI, 6.1%–8.4%) and 11.4% (95% CI, 10.0%–
12.8%); and for prostate cancer, 0.9% (95% CI, 0.5%–1.4%) and 2.0% (95% CI, 1.4%–2.7%). In
prospective analysis, the numbers of participants who newly met criteria for high-risk screening
based on family history per 100 persons followed up for 20 years were 2 (95% CI, 0–7) for
colorectal cancer, 6 (95% CI, 2–13) for breast cancer, and 8 (95% CI, 3–16) for prostate cancer.
The rate of change in cancer family history was similar for colorectal and breast cancer between
the 2 analyses.
Conclusion—Clinically relevant family history of colorectal, breast, and prostate cancer that
would result in recommendations for earlier or intense cancer screening increases between ages 30
and 50 years, although the absolute rate is low for prostate cancer.
One of the most effective tools to identify individuals at increased risk of cancer is to
ascertain their family history. For example, having 1 or more close relatives with colorectal
cancer increases risk from 2-fold to 6-fold.1–3 Individuals at increased risk of colorectal,
breast, or prostate cancer due to family history are recommended to begin screening for
these cancers earlier and in some cases using more sensitive methods than average risk
individuals. Those with family histories suggestive of rare hereditary cancer syndromes that
confer much higher risks may require even more intense screening or prevention regimens.4
It is estimated that 22% of individuals have a family history that suggests familial or
hereditary predisposition to cancer.5 The Agency for Healthcare Research and Quality
recommends that primary care clinicians collect a detailed family cancer history including
age at diagnosis for affected first- and second-degree relatives.6 Individuals with increased
familial risk should be informed of their risk, offered appropriate preventive and screening
strategies, and referred for genetic counseling and testing as indicated.
Little is known about how often clinically important changes in cancer family history occur
over time that would render an individual at increased risk and, therefore, a candidate for
earlier or intensive screening. To our knowledge, no prior reports have addressed this
question. This information is useful for determining how often family histories should be
updated by clinicians to inform recommendations for screening. In this study, we quantified
how often clinically significant changes in family history of breast, colorectal, or prostate
cancer occur throughout adulthood.
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We examined family history data among individuals enrolled in the Cancer Genetics
Network (CGN), a US national registry of individuals with a personal or family history of
cancer (predominantly breast, prostate, colorectal, and melanoma) established by the
National Cancer Institute in 1998.7 As detailed herein, we assessed changes in participants’
self-reported family history over 2 periods: (1) retrospectively, from birth until enrollment
into the CGN using family history data provided at entry and (2) prospectively, from
enrollment to time of last completed follow-up survey. We specifically examined changes in
family history that would render individuals candidates for earlier and more intense
screening for colorectal, breast, or prostate cancer based on current guidelines from the
American Cancer Society (ACS) (Table 1).
Screening Guidelines
Individuals at increased risk of colorectal cancer due to family history are recommended to
initiate colonoscopy screening at a younger age and to screen more frequently than those at
average risk (Table 1).9 For breast cancer screening, recent studies have demonstrated that
breast magnetic resonance imaging (MRI) has greater sensitivity for cancer detection than
mammography.10,11 The ACS guidelines recommend addition of annual breast MRI for
BRCA1/2 mutation carriers and those with at least a 20% to 25% lifetime risk of breast
cancer based on family history (Table 1).12 We used the Claus tables to identify family
histories associated with a lifetime breast cancer risk of 20% or greater.13 Having a brother
with prostate cancer is associated with a 3-fold increase in risk, and having 2 affected first-
degree relatives increases risk 5- to 10-fold.14 The ACS recommends men with 1 or more
first-degree relative with prostate cancer before age 65 years to consider prostate-specific
antigen (PSA) screening beginning at age 45 years (Table 1).15 We elected to use the ACS
guidelines because the ACS provides recommendations for high-risk screening for all 3
cancers of interest (including breast MRI), and these are widely used in clinical practice.
Moreover, the ACS guidelines for colorectal and breast cancer screening are identical to
those from the National Comprehensive Cancer Network.
Data Collected
The CGN enrolled 26 933 participants (with family history data on 540 578 family
members) at 14 academic research centers across the United States. Institutional review
boards at each center approved the study and participants provided written informed consent
to be contacted for long-term follow-up. Participants with various types of cancer were
ascertained both from local and state tumor registries (ie, population-based ascertainment)
and from high-risk cancer clinics. Some centers also recruited cases’ unaffected family
members. Only participants ascertained from population-based registries are included in
these analyses (n = 16 724). Furthermore, only data from the first enrolled member of each
family are included (n = 11 323).
At entry, participants completed a baseline questionnaire (in person or via telephone
interview or mail) eliciting information about sociodemographic characteristics, detailed
personal and 4-generation family cancer history, cancer-related medical history, and
smoking history. Participants at most centers indicated their racial and Hispanic background
via separate questions permitting participants to select up to 5 categories for racial/ethnic
heritage. Participants were contacted annually or biannually to update baseline information.
The median follow-up time was 8 years (range, 0–11 years).
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We used family history information reported at enrollment to construct a snapshot of
participants’ family cancer history as it changed from birth until CGN enrollment. For each
participant, we constructed a data set with an observation corresponding to each year of life
up until entry into the CGN, and for each year we evaluated whether he/she had clinically
relevant family history. For example, consider a participant who enrolled at age 45 years in
2000, with a father diagnosed as having colorectal cancer in 1985 at age 55 years. Thus,
prior to age 30 years (the participant’s age in 1985) the participant was not at increased risk,
and at age 30 years the participant would have met criteria for more intensive colorectal
cancer screening.
Using this data set, we then calculated the percentages of participants who would have met
the elevated risk screening guidelines at each year of age from birth until enrollment in the
registry. Ninety-five percent confidence intervals (CIs) for each age-specific estimate were
constructed using the binomial distribution. For comparison with the results from the
prospective analysis described below, the 10-year rate of those newly meeting high-risk
criteria for screening (number of participants per100whodid not meet criteria at the
beginning of the interval but met high-risk criteria sometime during 10 years of follow-up)
was calculated for each 10-year age interval.
Prospective Analysis
For this analysis, we evaluated how participants’ family cancer history changed
prospectively from CGN enrollment through their most recent follow-up. We determined the
number of participants who, at baseline, did not meet the criteria for high-risk screening.
Among these individuals (a subset of those in the retrospective analysis), we determined
how many would have been classified as meeting high-risk status as of their last follow-up.
To compute the 10-year rate among individuals for whom changes in their family history
resulted in their newly meeting criteria for earlier or more intensive screening, we divided
the number who met high-risk criteria by the total person-years of follow-up and multiplied
by 1000 to represent the number of participants per 100 who would have changed to meet
high-risk status for every 10 years of follow-up. Confidence intervals for these rates were
calculated using the Poisson distribution. We examined rates of meeting high-risk screening
criteria overall and stratified by participant age at baseline for comparison with the
retrospective analysis.
The prospective analyses were restricted on the basis of participant age at enrollment
because of the age-specific nature of the cancer screening criteria: colorectal cancer analysis
excluded registrants older than 50 years, prostate cancer analysis included men younger than
50 years, and breast cancer analysis included women aged 35 through 60 years (Table 1).
Participants with inadequate follow-up data were excluded from the prospective analysis.
Overall, about 22% of otherwise eligible participants were excluded because of missing
follow-up information (primarily at 1 large center) or an invalid follow-up date.
Each cancer screening–specific analysis excluded participants who reported the cancer of
interest at enrollment (for example, the MRI analyses excluded participants with breast
cancer) to compensate for the overrepresentation of cancer cases inherent in the tumor
registry–based population. These individuals were included in the other screening-specific
analyses given that the risks of breast, colorectal, and prostate cancer are relatively
independent from each other. Figure 1 depicts the inclusion/exclusion criteria for
participants in the retrospective and prospective analyses.
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This study used data from individuals enrolled in the CGN registry. Table 2 presents the
distribution of demographic characteristics and extent of family cancer history at baseline
for the 11 129 participants included in 1 or more of the retrospective cancer screening–
specific analyses. Participants included in the prospective analyses are a subset of this
population (Figure 1). The age distribution was fairly consistent across analyses, although
women in the breast cancer screening analysis tended to be younger than participants
included in the comparable colorectal and prostate cancer analyses. The distribution of race
and Hispanic ethnicity was comparable across analyses; however, there was less
representation in minority groups than in the general population.
Retrospective Analyses
We determined for each year of age from birth through enrollment in the CGN the
percentage of registrants who reported clinically relevant family history that would warrant
more intense cancer screening for colorectal, breast, and prostate cancer compared with
general population guidelines (Figure 2). Each participant contributed data at each yearly
point based on retrospective recreation of his/her family history from birth. At age 30 years,
2.1% of participants would have met criteria for early colonoscopy screening (95% CI,
1.8%–2.4%). By age 50 years, this percentage increased to 7.1% (95% CI, 6.5%–7.6%) and
peaked at age 70 years at approximately 11%. These estimates are also summarized by
decade in Table 3. The 10-year rates for newly meeting high-risk screening criteria based on
family history increased from 1 additional person per 100 individuals followed up
throughout their 20s, peaking at a rate of 3 additional people per 100 during their 40s.
Results from the retrospective breast cancer analysis show a pattern similar to the colorectal
cancer analysis, with steady increases in the percentage of participants who would have met
criteria for MRI screening through early and middle age, from 7.2% (95% CI, 6.1%–8.4%)
of women at age 30 years to 11.4% (95% CI, 10.0%–12.8%) at age 50 years. After age 60
years, the percentage leveled off at about 13%. The 10-year rates for newly meeting high-
risk criteria for screening were fairly even over the decades from ages 20 to 50 years at 3, 2,
and 3 additional persons per 100 followed up for 10 years among women aged 20 to 29, 30
to 39, and 40 to 49 years, respectively.
Although the retrospective prostate cancer analysis indicated similar findings of increasing
family history until age 60 years, the overall percentage of men who would have met criteria
for early PSA screening was much lower at only 0.9% (95% CI, 0.5%–1.4%) of men at age
30 years, and it increased only to 2.0% (95% CI, 1.4%–2.7%) by age 50 years. This could
reflect the low incidence of prostate cancer among men younger than 65 years, the family
history criterion that prompts PSA screening. As in the colorectal and breast cancer
analyses, the increase in the percentage of men with clinically relevant family history
leveled off around age 60 years at about 3%; similarly, the 10-year rates for newly meeting
high-risk screening criteria were lower for each age interval compared with the rates for
colorectal and breast cancer, remaining constant at 1 additional person who met high-risk
screening criteria per 100 followed up for 10 years for men aged 20 through 70 years.
Prospective Analyses
The prospective analyses assessed clinically relevant changes in family cancer history from
baseline (enrollment in the CGN) to the most recent follow-up (Table 4). The prospective
colorectal cancer analysis included data from 1533 participants who were younger than 50
years at enrollment, did not have a personal history of colorectal cancer, and met the other
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eligibility criteria described previously. During follow-up, 15 registrants reported changes in
family history that altered their risk, resulting in a 10-year rate of 1 (95% CI, 0–6) additional
person (who becomes eligible for enhanced screening) per 100 participants followed up for
10 years. The age-specific results suggest that more family history changes occur during the
30s (10-year rate, 2 per 100; 95% CI, 0–7) than the 40s (10-year rate, 1 per 100; 95% CI, 0–
6), although the CIs are fairly wide and overlapping.
The prospective breast MRI analysis included 617 women aged 35 through 65 years. The
overall rate of newly meeting criteria for more intensive screening was 3 (95% CI, 0–9)
additional women per 100 followed up for 10 years, with 10-year rates of 0 (95% CI, 0–4)
per 100 among women aged 35 to 39 years (when MRI screening starts), 4 (95% CI, 1–10)
per 100 for women aged 40 to 49 years, and 3 (95% CI, 0–9) per 100 for women aged 50 to
59 years.
The prospective PSA screening analysis included 163 men younger than 50 years, and the
rate of newly meeting criteria for more intensive screening was 4 (95% CI, 1–10) additional
men per 100 followed up for 10 years. The age-specific breakdown for the prostate analysis
results was similar to the earlier finding that the rate of change in family cancer history is
higher in early adulthood than in middle adulthood, with the 10-year rate of newly meeting
criteria for more intensive screening of 7 (95% CI, 3–14) per 100 for men younger than 30
years and 5 (95% CI, 2–12) per 100 for men aged 30 to 39 years compared with 3 (95% CI,
0–9) per 100 for men aged 40 to 49 years.
The rates of newly meeting criteria for more intensive screening for colorectal and breast
cancer obtained in the retrospective analyses were within the 95% CIs for the comparable
age-specific results of the prospective analyses presented in Table 4. However, for prostate
cancer, the rates of having first-reported family history that would meet criteria for more
enhanced screening in the retrospective analyses were substantially lower than those
obtained in the prospective analysis. For comparison with the retrospective rates of change
to high-risk status between ages 30 and 50 years, the overall 20-year rates from the
prospective analyses are 2 (95% CI, 0–7) per 100 for colorectal cancer, 6 (95% CI, 2–13)
per 100 for breast cancer, and 8 (95% CI, 3–16) per 100 for prostate cancer.
COMMENT
We evaluated the rate at which family cancer history changes over time with respect to
indicating the need for earlier or intensified screening for colorectal, breast, and prostate
cancer. Although family history of cancer was based on self-report, other groups have
confirmed the high quality of self-reported data.16 Participants with incomplete family
history information (such as unknown age of cancer diagnosis for a relative) were included,
as would be the case in the clinical setting, where determination of the need for cancer
screening is based on information provided by the patient. However, we acknowledge that
participants with a cancer diagnosis may be more motivated to provide accurate family
history in a study setting than in a clinic setting.
We used 2 complementary approaches with distinct sets of family history data obtained
within the same study population: retrospectively, from birth to enrollment, and
prospectively, from enrollment to last follow-up, in a large cohort of individuals followed up
to 10 years. Both analyses demonstrate that clinically relevant family history changes
substantially during early and middle adulthood, particularly for colorectal and breast
cancer, for which the percentage recommended for high-risk screening increases 1.5- to 3-
fold between ages 30 and 50 years. Results of the 2 prostate cancer analyses were not in
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complete agreement, possibly because of the limited data available, particularly for the
prospective analysis.
We have taken several steps to design our analyses so the results could be applied to the
general US population, although the CGN registry is underrepresented in participants from
racial and ethnic minorities and estimates in these populations may differ. For these
analyses, we included approximately two-thirds of the registrants who were ascertained via
population-based tumor registries. To attenuate the influence of our higher-than-average-risk
population, we excluded participants who had a diagnosis of the cancer of interest from the
screening-specific analyses. Thus, by excluding these participants, who are more likely to
have clinically relevant family history, our results may represent an underestimate of the
true rate of change in family history; however, we cannot rule out that our results are
overestimates due to the elevated cancer risk level inherent in our population. Scheuner et
al5 found that the percentage of adult women who met criteria for genetic evaluation for
hereditary breast cancer was similar but lower than ours (2%–4%), but this is not surprising
given that their measure was indication for genetic evaluation as opposed to indication for
MRI.
Other studies have documented that the majority of patients do not receive adequate familial
cancer risk assessment in primary care settings.8,17–20 Family health history data are more
likely to be collected at the initial clinic visit and are not adequately updated during follow-
up visits.21 These analyses are relevant principally to primary care clinicians, who are often
the first (or only) to initiate collection of family health history and are the main source of
referral for cancer screening, although they are also relevant for other physicians who
provide care to patients over many years. For this analysis, we only examined breast,
colorectal, and prostate cancer status and age at diagnosis among first- and second-degree
relatives. Subsequent updates require determining only whether there have been any new
diagnoses among living first- and second-degree relatives. These questions could be easily
added to standard patient questionnaires filled out during routine physician visits. Electronic
medical record systems could be designed to prompt physicians for periodic updates and
alert them to patients who now meet criteria for high-risk screening.
In our study, we found a 5% chance that an individual’s colorectal cancer screening
recommendation would change between ages 30 and 50 years based on family history and
that 4% of women would become candidates for MRI screening. Although there is
disagreement in the medical community regarding the merits of screening for prostate
cancer, family history of prostate cancer also increased over these age ranges. If a patient’s
family history is not updated during early and middle adulthood, the opportunity may be
missed to intervene with earlier or more intensive screening that maximizes the likelihood of
detecting cancer at an early, treatable stage.
Our study has several limitations. First, our determination of whether an individual would
meet criteria that would represent an increased risk level and therefore would be
recommended for earlier or intensive screening was based solely on reported changes in
family history of cancer over time. We did not address how many additional cancers would
be expected to be detected if appropriate screening based on the changing family history was
performed. Factors such as an individual’s personal medical history or prior cancer
screening results were not considered, and these issues also may change during adulthood
and need to be assessed by clinicians. Second, our study did not evaluate indications for
genetic risk assessment, although obtaining an accurate family history is also critical for
identifying patients who merit further genetic evaluation to reduce cancer morbidity in their
families. Third, our study did not assess whether participants who met criteria for high-risk
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screening based on family history and had recommendations for screening made by their
physicians actually had additional screening performed.
CONCLUSION
In summary, we found that family history of breast and colorectal cancer becomes
increasingly relevant in early adulthood, highlighting the need to obtain a comprehensive
family history at this time. We also found that family histories change significantly between
the ages of 30 and 50 years. We therefore recommend that family history should be updated
at least every 5 to 10 years to appropriately inform recommendations for cancer screening.
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Inclusion and Exclusion Criteria for Participants in the Retrospective and Prospective
Analyses
a Cancer-specific numbers of participants do not sum to total because some female
participants in the colorectal cancer analyses were also included in the breast cancer
analyses and some male participants in the colorectal cancer analyses were also included in
the prostate cancer analyses. Therefore, the total numbers reflect participants included in at
least 1 cancer-specific analysis.
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Results of Retrospective Analyses: Percentage of Participants With Clinically Significant
Cancer Family History by Participant Age
Solid lines indicate 95% confidence intervals.
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Table 1
American Cancer Society (ACS) Criteria and Screening Recommendations for Individuals at Increased Risk
Due to Family History





Colorectal ≥1 FDR diagnosed before age 60 y or ≥2
FDRs diagnosed at any age
Colonoscopy every 5 y, starting at age 40 y or 10 y before




Breastb ≥1 FDR diagnosed before age 30 y or ≥1
FDR and ≥1 SDR diagnosed before age
60 y or ≥2 FDRs with 1 diagnosed
before age 60 y and 1 diagnosed before
age 70 y
Annual magnetic resonance imaging in addition to
mammogram for women aged 35–60 y
Male; ovarian
cancer diagnosis
Prostate ≥1 FDR diagnosed before age 65 y Consider prostate-specific antigen blood test screening
starting at age 45 y
Female
Abbreviations: FDR, first-degree relative; SDR, second-degree relative.
a
Participants with cancer of interest were excluded from each analysis.
b
Criteria based on predicted lifetime breast cancer risk of at least 20% according to Claus tables.8
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Table 2
Distribution of Participant Characteristics at Cancer Genetics Network Enrollment by Cancer Screening
Subgroup (n = 11 129)
Characteristics








      <40 642 (7) 345 (14) 128 (7)
      40–49 1510 (15) 499 (20) 234 (13)
      50–59 2332 (24) 688 (27) 411 (23)
      60–69 2658 (27) 491 (19) 453 (25)
      70–79 2404 (24) 410 (16) 486 (27)
      ≥80 315 (3) 114 (5) 105 (6)
Race
      White 6957 (71) 1934 (76) 1398 (77)
      Black 431 (4) 99 (4) 50 (3)
      Asian 518 (5) 178 (7) 153 (8)
      Other 90 (1) 43 (2) 26 (1)
      Missing 1865 (19) 293 (12) 190 (11)
Hispanic ethnicity
      Yes 774 (8) 244 (10) 233 (13)
      No 7066 (72) 1982 (78) 1374 (75)
      Missing 2021 (20) 321 (12) 210 (12)
No. of affected first-degree relatives
      0 8841 (90) 2059 (81) 1645 (91)
      1 913 (9) 421 (17) 156 (9)
      2 82 (1) 49 (2) 13 (1)
      >2 17 (<1) 13 (1) 0
      Missing 8 (<1) 5 (<1) 3 (<1)
No. of affected second-degree relatives
      0 8316 (84) 1829 (72) 1606 (88)
      1 988 (10) 474 (19) 120 (7)
      2 156 (2) 110 (4) 12 (1)
      >2 44 (<1) 32 (1) 3 (<1)
      Missing 357(4) 102 (4) 76 (4)
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Table 3
Results From Retrospective Analyses: Participants With Clinically Significant Cancer Family History by Age






No. (%) [95% CI]
10-Year
Ratea
Colorectal (n = 9861)
      20 79 (0.8) [0.6–1.0]
      30 207 (2.1) [1.8–2.4] 1
      40 434 (4.4) [4.0–4.8] 2
      50 700 (7.1) [6.5–7.6] 3
      60 927 (9.4) [8.8–10.0] 2
      70 1075 (10.9) [10.3–11.6] 2
      80 1124 (11.4) [10.7–12.1] 1
Breast (n = 2547)
      20 110 (4.3) [3.5–5.2]
      30 183 (7.2) [6.1–8.4] 3
      40 227 (8.9) [7.6–10.1] 2
      50 290 (11.4) [10.0–12.8] 3
      60 321 (12.6) [11.2–14.2] 1
      70 339 (13.3) [11.9–14.9] 1
      80 341 (13.4) [11.9–15.0] 0
Prostate (n = 1817)
      20 2 (0.1) [0–0.4]
      30 16 (0.9) [0.5–1.4] 1
      40 27 (1.5) [1.0–2.2] 1
      50 36 (2.0) [1.4–2.7] 1
      60 53 (2.9) [2.2–3.8] 1
      70 62 (3.4) [2.6–4.4] 1
      80 64 (3.5) [2.7–4.5] 0
Abbreviation: CI, confidence interval.
a
The 10-year rate was calculated as the number of participants who newly met increased-risk criteria per 100 followed up for 10 years.
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Table 4












      18–29 72 511 0 0 (0–4)
      30–39 359 2444 4 2 (0–7)
      40–49 1102 8021 11 1 (0–6)
      Overall 1533 10 976 15 1 (0–6)
Breast
      35–39 66 482 0 0 (0–4)
      40–49 223 1649 7 4 (1–10)
      50–59 328 2361 6 3 (0–9)
      Overall 617 4493 13 3 (0–9)
Prostate
      18–29 18 134 1 7 (3–14)
      30–39 35 219 1 5 (2–12)
      40–49 110 782 2 3 (0–9)
      Overall 163 1135 4 4 (1–10)
Abbreviation: CI, confidence interval.
a
The 10-year rate was calculated as the number of participants who newly met increased-risk criteria per 100 followed up for 10 years.
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